Biocon Biologics wins ‘ABEA : Bioprocessing Excellence in South Asia’ Award

The company garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey

0
92
Bengaluru: Biocon Biologics, a subsidiary of Biocon has won the prestigious ‘Bioprocessing Excellence in South Asia’ Award at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023 held in Singapore earlier this month.
The company is a frontrunner in the global biosimilars industry and is committed to scientific innovation, the highest standards of quality compliance and global scale manufacturing capabilities to serve patients and healthcare systems across the globe.
Commenting on the development, Kiran Kumar Gandhirajan, Site Head, Biocon Malaysia, said, “We are delighted and proud to receive the ‘Bioprocessing Excellence in South Asia’ Award. It is a recognition of our longstanding expertise in process sciences, state-of-the-art manufacturing capabilities, operational excellence and high standards of quality compliance. These strengths have enabled us to expand patient access to high quality affordable biosimilars and make a meaningful difference to global healthcare.”
Biocon Biologics was recognized as the winner as it garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey. The annual Asia-Pacific Bioprocessing Excellence Awards organized by IMAPAC, recognize organizations who demonstrate exceptional bioprocessing expertise and the use of best-in-class technologies and practices to achieve biomanufacturing excellence in terms of speed, reduced cost, and superior quality.
Biocon Biologics has developed multiple technology platforms that use various expression systems such as bacteria, yeast, and mammalian cells.
The Pichia Pastoris platform technology used to express recombinant proteins is a proprietary technology developed by Biocon and used for its recombinant human insulin and insulin analog products. Similarly, the company’s scalable mammalian CHO and NSO cell-based expression platforms and robust process science expertise allow it to develop and manufacture both novel and biosimilar monoclonal antibodies for global markets.